We provide you with 20 years of free, institutional-grade data for SVRA stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of SVRA. Explore the full financial landscape of SVRA stock.
Reported Date | CIK | Ticker | Type | |
---|---|---|---|---|
2025-08-13 | 1160308 | SVRA | 10-Q | Url |
2025-05-13 | 1160308 | SVRA | 10-Q | Url |
2025-03-27 | 1160308 | SVRA | 10-K | Url |
2024-11-12 | 1160308 | SVRA | 10-Q | Url |
2024-08-12 | 1160308 | SVRA | 10-Q | Url |
2024-05-09 | 1160308 | SVRA | 10-Q | Url |
2024-03-07 | 1160308 | SVRA | 10-K | Url |
2023-11-09 | 1160308 | SVRA | 10-Q | Url |
2023-08-10 | 1160308 | SVRA | 10-Q | Url |
2023-05-15 | 1160308 | SVRA | 10-Q | Url |
2023-03-30 | 1160308 | SVRA | 10-K | Url |
2022-11-10 | 1160308 | SVRA | 10-Q | Url |
2022-08-11 | 1160308 | SVRA | 10-Q | Url |
2022-05-11 | 1160308 | SVRA | 10-Q | Url |
2022-03-30 | 1160308 | SVRA | 10-K | Url |
2021-11-12 | 1160308 | SVRA | 10-Q | Url |
2021-08-12 | 1160308 | SVRA | 10-Q | Url |
2021-05-13 | 1160308 | SVRA | 10-Q | Url |
2021-03-10 | 1160308 | SVRA | 10-K | Url |
2020-11-05 | 1160308 | SVRA | 10-Q | Url |
2020-08-06 | 1160308 | SVRA | 10-Q | Url |
2020-05-07 | 1160308 | SVRA | 10-Q | Url |
2020-03-12 | 1160308 | SVRA | 10-K | Url |
2019-11-07 | 1160308 | SVRA | 10-Q | Url |
2019-08-08 | 1160308 | SVRA | 10-Q | Url |
2019-05-09 | 1160308 | SVRA | 10-Q | Url |
2019-03-13 | 1160308 | SVRA | 10-K | Url |
2018-11-07 | 1160308 | SVRA | 10-Q | Url |
2018-08-09 | 1160308 | SVRA | 10-Q | Url |
2018-05-09 | 1160308 | SVRA | 10-Q | Url |
2018-03-14 | 1160308 | SVRA | 10-K | Url |
2017-11-08 | 1160308 | SVRA | 10-Q | Url |
2017-08-09 | 1160308 | SVRA | 10-Q | Url |
2017-05-09 | 1160308 | SVRA | 10-Q | Url |
2017-03-06 | 1160308 | SVRA | 10-K | Url |
2016-11-08 | 1160308 | SVRA | 10-Q | Url |
2016-08-09 | 1160308 | SVRA | 10-Q | Url |
2016-05-06 | 1160308 | SVRA | 10-Q | Url |
2016-03-14 | 1160308 | SVRA | 10-K | Url |
2015-11-12 | 1160308 | SVRA | 10-Q | Url |
2015-08-12 | 1160308 | SVRA | 10-Q | Url |
2015-05-11 | 1160308 | SVRA | 10-Q | Url |
2015-03-24 | 1160308 | SVRA | 10-K | Url |
2014-10-31 | 1160308 | SVRA | 10-Q | Url |
2014-08-11 | 1160308 | SVRA | 10-Q | Url |
2014-05-05 | 1160308 | SVRA | 10-Q | Url |
2014-03-26 | 1160308 | SVRA | 10-K | Url |
2013-11-04 | 1160308 | SVRA | 10-Q | Url |
2013-08-05 | 1160308 | SVRA | 10-Q | Url |
2013-05-28 | 1160308 | SVRA | S-1 | Url |
2013-05-15 | 1160308 | SVRA | 10-Q | Url |
2013-03-19 | 1160308 | SVRA | 10-K | Url |
2012-11-05 | 1160308 | SVRA | 10-Q | Url |
2012-08-06 | 1160308 | SVRA | 10-Q | Url |
2012-05-07 | 1160308 | SVRA | 10-Q | Url |
2012-03-08 | 1160308 | SVRA | 10-K | Url |
2011-11-08 | 1160308 | SVRA | 10-Q | Url |
2011-08-08 | 1160308 | SVRA | 10-Q | Url |
2011-05-09 | 1160308 | SVRA | 10-Q | Url |
2011-03-10 | 1160308 | SVRA | 10-K | Url |
2010-11-08 | 1160308 | SVRA | 10-Q | Url |
2010-08-10 | 1160308 | SVRA | 10-Q | Url |
2010-04-30 | 1160308 | SVRA | 10-Q | Url |
2010-03-18 | 1160308 | SVRA | 10-K | Url |
2009-11-10 | 1160308 | SVRA | 10-Q | Url |
2009-08-12 | 1160308 | SVRA | 10-Q | Url |
2009-07-24 | 1160308 | SVRA | S-1 | Url |
2009-05-15 | 1160308 | SVRA | 10-Q | Url |
2009-03-27 | 1160308 | SVRA | 10-K | Url |
2008-11-07 | 1160308 | SVRA | 10-Q | Url |
2008-08-11 | 1160308 | SVRA | 10-Q | Url |
2008-05-12 | 1160308 | SVRA | 10-Q | Url |
2008-03-17 | 1160308 | SVRA | 10-K | Url |
2007-11-07 | 1160308 | SVRA | 10-Q | Url |
2007-08-07 | 1160308 | SVRA | 10-Q | Url |
2007-05-08 | 1160308 | SVRA | 10-Q | Url |
2007-03-15 | 1160308 | SVRA | 10-K | Url |
2006-11-09 | 1160308 | SVRA | 10-Q | Url |
2006-08-09 | 1160308 | SVRA | 10-Q | Url |
2006-05-10 | 1160308 | SVRA | 10-Q | Url |
2006-03-16 | 1160308 | SVRA | 10-K | Url |
2005-11-14 | 1160308 | SVRA | 10-Q | Url |
2005-08-12 | 1160308 | SVRA | 10-Q | Url |
2005-05-16 | 1160308 | SVRA | 10-Q | Url |
Savara Inc(NASDAQ:SVRA)

Savara Inc. operates as an orphan lung disease company. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Aus...
Website: http://www.savarapharma.com
Founded: 1995
Full Time Employees: 36
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about SVRA stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.